BIOMAT Database Logo BIOMAT Database Logo

New platelet aggregation inhibitors based on pyridazinone moiety. 2015

Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
Departamento de Química Orgánica, Universidade de Vigo, 36310 Vigo, Spain; Instituto de Investigación Biomédica (IBI), Universidade de Vigo, 36310 Vigo, Spain.

New series of pyridazinone derivatives (4, 5 and 6) were synthesized in good yields following a synthetic strategy based on singlet oxygen oxidation of alkyl furans, in which a suitable β(α)-substituted γ-hydroxybutenolide (10 or 11) or a bicyclic lactone (12 or 13) was the key intermediate. The synthesized compounds were tested in vitro as antiplatelet agents and some of them (compounds 4b, 4d and 5b) exhibited potent inhibitory effects on collagen-induced platelet aggregation with IC50 values in the low μM range. Studies performed with the most active compound of these series (4b) demonstrated its lack of activity as inhibitor of platelet aggregation induced by other agonists as thrombin, ionomycin or U-46619 suggesting a selective action on the biochemical mechanisms triggered by collagen in the platelets.

UI MeSH Term Description Entries
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013917 Thrombin An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN. Thrombase,Thrombin JMI,Thrombin-JMI,Thrombinar,Thrombostat,alpha-Thrombin,beta,gamma-Thrombin,beta-Thrombin,gamma-Thrombin,JMI, Thrombin

Related Publications

Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
New platelet aggregation inhibitors.
December 1989, Chemical & pharmaceutical bulletin,
Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
Thienopyrimidine-based P2Y12 platelet aggregation inhibitors.
October 2009, Bioorganic & medicinal chemistry letters,
Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
New carbamoylpiperidines as human platelet aggregation inhibitors.
May 2000, Bioorganic & medicinal chemistry,
Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
[Platelet aggregation inhibitors].
December 1981, Revue de l'infirmiere,
Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
New pyrazolylhydrazone derivatives as inhibitors of platelet aggregation.
July 1993, The Journal of pharmacy and pharmacology,
Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
Supercooperativity in platelet aggregation: substituted pyridyl isoxazoles, a new class of supercooperative platelet aggregation inhibitors.
September 1994, FEBS letters,
Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
Substituted pyrazolylhydrazones: a new class of platelet aggregation inhibitors.
January 1991, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities.
January 2010, Archives of pharmacal research,
Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
Effect of some inhibitors of platelet aggregation on platelet nucleotides.
September 1969, The Biochemical journal,
Tamara Costas, and María Carmen Costas-Lago, and Noemí Vila, and Pedro Besada, and Ernesto Cano, and Carmen Terán
Design, Synthesis and Investigation of New Diphenyl Substituted Pyridazinone Derivatives as Both Cholinesterase and Aβ-Aggregation Inhibitors.
January 2019, Medicinal chemistry (Shariqah (United Arab Emirates)),
Copied contents to your clipboard!